Household Air Pollution and Health: A Multi-country LPG Intervention Trial (HAPIN)

March 22, 2024 updated by: Thomas Clasen, Emory University
This study is a randomized controlled trial of liquefied petroleum gas (LPG) stove and fuel distribution in 3,200 households in four countries (India, Guatemala, Peru, and Rwanda). Following a common protocol, each intervention site will recruit 800 pregnant women (aged 18-34 years, 9 - <20 weeks gestation), and will randomly assign half their households to receive LPG stoves and an 18-month supply of LPG. Control households are anticipated to continue to cook primarily with solid biomass fuels, and will receive compensation based on a uniform set of trial-wide principles, customized to each site based on formative research. The mother will be followed along with her child until the child is 1 year old. The researchers estimate that 15% of households will have a second, non-pregnant older adult woman (aged 40 to <80 years) who will also be enrolled at baseline and followed during the 18-month follow-up period. To optimize intervention use, the researchers will implement behavior change strategies informed by previous experiences and formative research in Year 1. This study will assess cookstove use, conduct repeated personal exposure assessments of household air pollution, and collect dried blood spots and urinary samples for biomarker analysis and biospecimen storage. The primary outcomes are low birth weight, severe pneumonia incidence, and stunting of the child, and blood pressure in the older adult woman. Secondary outcomes include preterm birth and development in the child, maternal blood pressure during pregnancy, and endothelial function, respiratory impairment, atherosclerosis, carcinogenic metabolites, and quality of life in the older adult woman. Participants in India, Guatemala and Rwanda will be followed until the child is 5 years old to assess the longer-term effects of the intervention.

Study Overview

Status

Active, not recruiting

Detailed Description

Globally, nearly 3 billion people rely on solid fuels for cooking and heating, the vast majority in low- and middle-income countries (LMICs). The resulting household air pollution (HAP) is the third leading risk factor in the 2010 global burden of disease, accounting for an estimated 4.3 million deaths annually, largely among women and young children. Previous interventions have provided cleaner biomass-based cookstoves, but have failed to reduce exposure to levels that produce meaningful health improvements. There have been no large-scale field trials with liquefied petroleum gas (LPG) cookstoves, likely the cleanest scalable intervention.

The aim of this study is to conduct a randomized controlled trial of LPG stove and fuel distribution in 3,200 households in four LMICs (India, Guatemala, Peru, and Rwanda) to deliver rigorous evidence regarding potential health benefits across the lifespan. Each intervention site will recruit 800 pregnant women (aged 18-34 years, 9 - <20 weeks gestation), and will randomly assign half their households to receive LPG stoves and an 18-month supply of LPG. Control households are anticipated to continue to cook primarily with solid biomass fuels, and will receive compensation based on a uniform set of trial-wide principles, customized to each site based on formative research. The mother will be followed along with her child until the child is 1 year old. In households with a second, non-pregnant older adult woman (aged 40 to <80 years) the researchers will also enroll and follow her during the 18-month follow-up period in order to assess cardiopulmonary, metabolic, and cancer outcomes. To optimize intervention use, the researchers will implement behavior change strategies. This study will assess cookstove use, conduct repeated personal exposure assessments to HAP (PM2.5, black carbon, carbon monoxide), and collect dried blood spots and urinary samples for biomarker analysis and biospecimen storage on all participants at multiple time points. The primary outcomes are low birth weight, severe pneumonia incidence, and stunting of the child, and blood pressure in the older adult woman. Secondary outcomes include preterm birth and development in the child, maternal blood pressure during pregnancy, and endothelial function, respiratory impairment, atherosclerosis, carcinogenic metabolites, and quality of life in the older adult woman.

This study will address the following specific aims: (1) using an intent-to-treat analysis, determine the effect of a randomized LPG stove and fuel intervention on health in four diverse LMIC populations using a common protocol; (2) determine the exposure-response relationships for HAP and health outcomes; and (3) determine relationships between LPG intervention and both targeted and exploratory biomarkers of exposure/health effects.

This study will provide evidence, including costs and implementation strategies, to inform national and global policies on scaling up LPG stoves among vulnerable populations. Ultimately, this will facilitate deeper policy-level discussions as well as identify requirements for initiating and sustaining HAP interventions globally.

The intervention delivery occurred until the child was one year of age. The researchers will continue to follow participants in India, Guatemala and Rwanda until the child is 5 years old to assess the longer-term effects of the intervention. Previous evidence suggests that the benefits of reduced exposure during the first, critical year of development will continue even if the intervention ends. The researchers will continue using methods employed during the HAPIN trial period. The HAPIN trial provides a unique context in which to address these questions, particularly given the successful intervention and exposure reduction. Participants are well-characterized and health and exposures to air pollution are being documented. Critically, because of its experimental design of the trial, continued follow-up of the cohort will provide rigorous causal inferences about the effects of this 500-day intervention over the most important period of early childhood development.

Study Type

Interventional

Enrollment (Actual)

3640

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Guatemala, Guatemala, 01015
        • Universidad del Valle de Guatemala
    • Tamil Nadu
      • Chennai, Tamil Nadu, India, 600116
        • Sri Ramachandra Institute of Higher Education and Research
      • Puno, Peru
        • Puno Global Non-Communicable Disease Research Site, School of Medicine, Johns Hopkins University
      • Kigali, Rwanda
        • Rwanda Research Site, London School of Hygiene and Tropical Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 79 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria for Pregnant Women:

  • Confirmed pregnancy (hCG positive blood or urine test)
  • Aged 18 to <35 years (via self-report)
  • Uses biomass stove predominantly
  • Lives in study area
  • 9 - <20 weeks gestation confirmed by ultrasound
  • Singleton pregnancy (one fetus)
  • Viable fetus with normal fetal heart rate (120-180 beats per minute) at time of ultrasound
  • Continued pregnancy at the time of randomization confirmed by self-report
  • Agrees to participate with informed consent

Exclusion Criteria for Pregnant Women:

  • Currently smokes cigarettes or other tobacco products
  • Plans to move permanently outside study area in the next 12 months
  • Uses LPG stove predominantly, or is likely to use LPG predominantly in the near future

Inclusion Criteria for Older Adult Woman in the Same Household:

  • Aged 40 to <80 years (via self-report)

Exclusion Criteria for Older Adult Woman in the Same Household:

  • Currently smokes cigarettes or other tobacco products
  • Pregnant (by self-report)
  • Plans to move out of her current household in the next 12 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Liquefied petroleum gas cookstove
Participants randomized to the experimental arm will receive a liquefied petroleum gas (LPG) cookstove and 18-month supply of LPG.
The intervention consists of a high-quality locally-available liquefied petroleum gas (LPG) stove having at least two burners, a continuous supply of LPG fuel for 18 months, and the promotion of stove use on an exclusive basis for cooking. The intervention will be provided free of charge to all intervention households upon enrollment. On a weekly basis, study staff will examine stove condition, perform any repairs necessary, and measure and record weight of LPG tanks in order to anticipate need for refills.
No Intervention: Control
Participants in the control group will not receive a liquefied petroleum gas (LPG) stove and will continue using traditional cooking methods (open fire or traditional stoves), or the cooking method of their choice. Control households will receive compensation based on a uniform set of trial-wide principles, customized to each site based on formative research.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Length-for-age z-score 2 standard deviations below the standard
Time Frame: 12 months after birth
The primary outcome measured is stunting at one year of age, defined as a length-for-age z-score (LAZ) that is 2 standard deviations below the median of the growth standard. Infant length will be assessed at birth and quarterly thereafter, until the child is 12 months old. Z-scores will be calculated using the 2006 World Health Organization (WHO) Multi-Growth Reference Standard (MGRS).
12 months after birth
Birth weight
Time Frame: Within 24 hours of birth (up to 5 months post-randomization of mother)
Birth weight will be assessed by a trained nurse or health worker within 24 hours of birth. Infants will be weighed naked or in a pre-weighed blanket. Weight will be measured to the nearest 10 g using a digital electronic scale, if performed by the study field staff; otherwise, hospital medical records will be used.
Within 24 hours of birth (up to 5 months post-randomization of mother)
Incidence of HAPIN Defined Severe Pneumonia
Time Frame: Up to 12 months after birth
The number of times a child has severe pneumonia over their period of follow-up during the first year of life will be assessed. HAPIN pneumonia criteria are adapted from the WHO classification of childhood pneumonia (2014) and there are 3 algorithms for HAPIN case criteria: 1) the presence of cough and/or difficult breathing and at least 1 general danger sign plus evidence of pneumonia on lung imaging (i.e., lung ultrasound or chest x-ray), or 2) the presence of cough and/or difficult breathing and hypoxemia (measured either via pulse oximetry (SpO2), or observing a child requiring advanced respiratory support (i.e., intubation and mechanical ventilation, non-invasive ventilation with continuous or bi-level positive airway pressure support, or high-flow nasal cannula oxygen), or 3) children who die prior to evaluation but their death is attributed to pneumonia by verbal autopsy. Cases of pneumonia are recorded children present to HAPIN health facilities with respiratory symptoms.
Up to 12 months after birth
Change in Systolic Blood Pressure
Time Frame: Baseline, 3, 5, 9, 12, and 18 months post-randomization, 24, 36, 48, and 60 months of age
Systolic blood pressure will be assessed in the older adult women in the intervention and control arms using automatic sphygmomanometers (Omron HEM-907XL; Osaka, Japan). The study team will use the procedures adapted from previously validated methods and cardiovascular outcome studies, following recommendations for the American Heart Association and the European Society of Hypertension.
Baseline, 3, 5, 9, 12, and 18 months post-randomization, 24, 36, 48, and 60 months of age
Change in Child Linear Growth
Time Frame: Birth (3-5 months post-randomization), 3, 6, 9, 12, 24, 36, 48 and 60 months of age
Linear growth of children will be assessed in centimeters of height from the time of birth until 60 months of age.
Birth (3-5 months post-randomization), 3, 6, 9, 12, 24, 36, 48 and 60 months of age
Change in Caregiver Reported Early Childhood Development Instrument (CREDI) Score
Time Frame: 3 months of age to 24 months of age
Child development will be assessed with the Caregiver Reported Early Childhood Development Instrument (CREDI). The CREDI is a population-level measure of early childhood development (ECD) for children from 0-2 years of age. The CREDI assesses 5 domains of child development: 1) motor development (fine and gross motor), 2) language development (expressive and receptive language), 3) cognitive development (executive function, problem solving and reasoning, and pre-academic knowledge), 4) socio-emotional development (emotional and behavioral self-regulation, emotional knowledge, and social competence), and 5) mental health (internalizing and externalizing behaviors). The CREDI long form has 117 items and the number of questions answered depends on the age of the child. Responses of "yes" are coded as 1 and "no" is coded as 0; certain items are reverse coded. Total raw scores increase by age (with developmental progression), and higher scores indicate increased development.
3 months of age to 24 months of age
Change in Malawi Developmental Assessment Tool (MDAT) Score
Time Frame: 36, 48 and 60 months of age
The MDAT measures gross motor (39 items), fine motor (42 items), language/cognition (40 items) and social skills (36 items). Originally developed and validated in rural Malawi, it has now been used in over 25 countries with more than 8,000 children as both a clinical and research tool. The MDAT is a continuous test with start and stop rules. Most items are administered directly to the child and items that are not easily observed (e.g., child speaks in full sentences; child understands sharing with others; child can dress self) are administered by parent report. Children receive either a pass or fail for each item, and summed pass scores can produce a composite score as well as domain-specific scores. Total scores range from 0 to 157 where higher scores indicate greater neurodevelopment.
36, 48 and 60 months of age

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Preterm birth
Time Frame: Up to 5 months (within 24 hours of birth, 3-5 months post randomization)
Preterm birth is defined as delivery of a living infant prior to 37 completed weeks of gestation.
Up to 5 months (within 24 hours of birth, 3-5 months post randomization)
Hospitalization for respiratory illness
Time Frame: Up to 12 months after birth
Cumulative incidence of hospitalizations for a respiratory illness during the first year of life.
Up to 12 months after birth
Change in Maternal Blood Pressure
Time Frame: Baseline (9-20 weeks gestation), 24-28 and 32-36 weeks gestation, 24, 36, 48 and 60 months of age
Blood pressure will be assessed in the pregnant women in the intervention and control arms using automatic sphygmomanometers (OMRON HEM-907XL; Osaka, Japan). After delivery, blood pressure will be measured in the new mothers when the child is 24, 36, 48 and 60 months old. The study team will use the procedures adapted from previously validated methods and cardiovascular outcome studies, following recommendations for the American Heart Association and the European Society of Hypertension.
Baseline (9-20 weeks gestation), 24-28 and 32-36 weeks gestation, 24, 36, 48 and 60 months of age
Change in Diastolic blood pressure
Time Frame: Baseline, 3, 6, 12 and 18 months post-randomization, 24, 36, 48, and 60 months of age
Diastolic blood pressure will be assessed in the older adult women and new mothers in the intervention and control arms using automatic sphygmomanometers (Omron HEM-907XL; Osaka, Japan). The study team will use the procedures adapted from previously validated methods and cardiovascular outcome studies, following recommendations for the American Heart Association and the European Society of Hypertension.
Baseline, 3, 6, 12 and 18 months post-randomization, 24, 36, 48, and 60 months of age
Mean arterial pressure
Time Frame: Baseline, 3, 6, 12 and 18 months post-randomization, 24, 36, 48, and 60 months of age
Mean arterial pressure will be assessed in the older adult women and new mothers in the intervention and control arms using automatic sphygmomanometers (Omron HEM-907XL; Osaka, Japan). Mean arterial pressure is calculated as DBP+(SBP-DBP)/3, where SBP=systolic blood pressure and DBP=diastolic blood pressure.
Baseline, 3, 6, 12 and 18 months post-randomization, 24, 36, 48, and 60 months of age
Pulse pressure
Time Frame: Baseline, 3, 6, 12 and 18 months post-randomization, 24, 36, 48, and 60 months of age
Pulse pressure will be assessed in the older adult women and new mothers in the intervention and control arms using automatic sphygmomanometers (Omron HEM-907XL; Osaka, Japan). pressure. Pulse pressure is the difference between systolic blood pressure and diastolic blood pressure.
Baseline, 3, 6, 12 and 18 months post-randomization, 24, 36, 48, and 60 months of age
Fetal Growth
Time Frame: Baseline, Gestation Week 24-28 and Gestation Week 32-36
Pregnant women will have ultrasounds at Baseline and during gestation weeks 24-28 and gestation weeks 32-36 to measure fetal growth outcomes. Specifically, we will evaluate head circumference (HC), abdominal circumference (AC), femur length (FL) and estimated fetal weight (EFW) during gestation. We will compare (i) z-scores of individual fetal growth measurements (HC, AC, FL, EFW) at the 2 growth ultrasound visits between intervention and control participants (separately at 24-28 wks gestation and 32-36 wks gestation); (ii) differences in proportions of the 2.5th percentiles of each of these measurements evaluated separately at 24-28 and 32-36 weeks gestation; (iii) Z-score trajectories of HC, AC, FL and EFW as a function of gestational age and intervention; and (iv) prevalence of small for gestational age (SGA) during the fetal period through birth as measured by WHO INTERGROWTH 21st standards.
Baseline, Gestation Week 24-28 and Gestation Week 32-36
Gestational age at birth
Time Frame: Up to 5 months (within 24 hours of birth, 3-5 months post randomization)
In weeks, as continuous outcome, among all live births.
Up to 5 months (within 24 hours of birth, 3-5 months post randomization)
WHO Non-severe Pneumonia
Time Frame: Up to 12 months after birth
Cumulative incidence of WHO non-severe pneumonia (2014 definition and 2013 definition) during the first year of life. Cases of pneumonia are recorded whenever children present to HAPIN health facilities with respiratory symptoms.
Up to 12 months after birth
WHO Severe Pneumonia
Time Frame: Up to 12 months after birth
Cumulative incidence of WHO non-severe pneumonia (2014 definition and 2013 definition) during the first year of life. Cases of pneumonia are recorded whenever children present to HAPIN health facilities with respiratory symptoms.
Up to 12 months after birth
WHO Pocket Book Non-severe Pneumonia
Time Frame: Up to 12 months after birth
Cumulative incidence of WHO non-severe pneumonia during the first year of life, as defined in the second edition of the "Pocket book of hospital care for children" (2013). Cases of pneumonia are recorded whenever children present to HAPIN health facilities with respiratory symptoms.
Up to 12 months after birth
WHO Pocket Book Severe Pneumonia
Time Frame: Up to 12 months after birth
Cumulative incidence of WHO severe pneumonia during the first year of life, as defined in the second edition of the "Pocket book of hospital care for children" (2013). Cases of pneumonia are recorded whenever children present to HAPIN health facilities with respiratory symptoms.
Up to 12 months after birth
Hypoxemic Pneumonia
Time Frame: Up to 12 months after birth
Cumulative incidence of hypoxemic pneumonia during the first year of life. Cases of pneumonia are recorded whenever children present to HAPIN health facilities with respiratory symptoms.
Up to 12 months after birth
Ultrasound or Radiograph Pneumonia
Time Frame: Up to 12 months after birth
Cumulative incidence of lung ultrasound or chest radiograph pneumonia during the first year of life. Cases of pneumonia are recorded whenever children present to HAPIN health facilities with respiratory symptoms.
Up to 12 months after birth
Change in Brachial artery reactivity testing (BART)
Time Frame: Baseline, 18 months
Brachial artery reactivity testing (BART) measures endothelial function via flow-mediated dilatation to reactive hyperemia following the release of arm blood-flow occlusion. In this test, baseline artery diameter is measured, then a blood pressure cuff is inflated to induce distal arm ischemia for 5 minutes and after releasing the pressure, the post-occlusion brachial artery diameter is measured. The ratio of post- to pre-occlusion artery diameter represents endothelial function where lower values indicate worse endothelial function. (Peru only)
Baseline, 18 months
Change in Carotid intima-media thickness (CIMT)
Time Frame: Baseline, 18 months post-randomization, and when child is 24 months of age
The carotid intima-media thickness test (CIMT) is used to determine the extent of carotid atherosclerotic vascular disease. The test measures the thickness of the inner two layers of the carotid artery and can detect plaque build up prior to physical symptoms being experienced. The carotid ultrasound will be performed with a portable ultrasound by trained sonographers.
Baseline, 18 months post-randomization, and when child is 24 months of age
Change in St. George Respiratory Questionnaire (SGRQ) Score
Time Frame: Baseline, 18 months
Adult respiratory health and well-being will be assessed with the St. George Respiratory Questionnaire (SGRQ). The SGRQ measures impaired health and perceived well-being among individuals with chronic airway disease. The SGRQ has sections assessing symptoms, activities that cause breathlessness or are limited because of breathlessness, and the impacts of respiratory problems on employment, sense of control of health, panic, stigmatization, medication use, side effects of therapies, expectations for health and disturbances of daily life. The questionnaire includes multiple choice, true/false and open-ended questions.
Baseline, 18 months
Change in Short Form 36 Survey (SF-36) Score
Time Frame: Baseline, 18 months
The Short Form 36 survey (SF-36) is a standardized, preference-based 36 item questionnaire evaluating quality of life. The survey has 8 sections (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health). Possible scores range from 0 (lowest quality of life) to 100 (highest quality of life).
Baseline, 18 months
Change in Weight
Time Frame: Baseline, 3, 6, 9, 12 and 18 months post-randomization, 24, 36, 48 and 60 months of age
Weight will be measured in the pregnant women/new mothers, the older adult women, and the children. Weight is measured in kilograms (kg). Weight in pregnant women will be measured at baseline, 24-28 weeks gestation, and 32-36 weeks gestation, and in new mothers when the child is 24- and 36-months old. In older adult women, it will be measured at baseline, 3, 6, 9, 12 and 18 months post-randomization, and when the child is 24-months old. Weight in children will be measured at birth, and at 3, 6, 9, 12, 24, 36, 48 and 60 months of age.
Baseline, 3, 6, 9, 12 and 18 months post-randomization, 24, 36, 48 and 60 months of age
Change in Body Mass Index (BMI)
Time Frame: Baseline, 3, 6, 9, 12 and 18 months post-randomization, 24, 36, 48 and 60 months of age
BMI will be calculated for the pregnant women, the older adult women, and the children. BMI is calculated as weight in kilograms divided by height in meters (m) squared (kg/m²). BMI in pregnant women will be calculated at baseline, 24-28 weeks gestation, and 32-36 weeks gestation, and in new mothers when the child is 24- and 36-months old. In older adult women, it will be calculated at baseline, 3, 6, 9, 12 and 18 months post-randomization, and when the child is 24-months old. Weight in children will be calculated at birth, and at 3, 6, 9, 12, 24, 36, 48 and 60 months of age.
Baseline, 3, 6, 9, 12 and 18 months post-randomization, 24, 36, 48 and 60 months of age
Change in Height
Time Frame: Baseline, 3, 6, 9, 12 and 18 months post-randomization, 24 months of age
Height in women will be measured in centimeters. Height in pregnant women will be measured at baseline, 24-28 weeks gestation, and 32-36 weeks gestation, and in new mothers when the child is 24- and 36-months old. In older adult women, it will be measured at baseline, 3, 6, 9, 12 and 18 months post-randomization, and when the child is 24-months old. This measurement will be used to compute the body mass index.
Baseline, 3, 6, 9, 12 and 18 months post-randomization, 24 months of age
Change in Urinary Biomarkers
Time Frame: Baseline, 3, 6, 9, 12 and 18 months post-randomization, 3, 6, 12 and 24 months of age
Multiple exposure biomarkers will be measured: 3-OH Cotinine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), levoglucosan, 8OH-deoxyguanosine (8OHdG), and Volatile Organic Chemicals (VOC) metabolites. Exposure biomarkers (especially for children whose urine may be limited) will be prioritized as follows: polycyclic aromatic hydrocarbon (PAH) biomarkers, levoglucosan, volatile organic chemicals (VOC) biomarkers, heavy metals, and tobacco-related biomarkers. Urinary biomarkers will be measured in pregnant women at baseline, 24-28 weeks gestation, and 32-36 weeks gestation, and in new mothers when the child is 24-months old. Biomarkers will be measured in older adult women at baseline, 3, 6, 9, 12 and 18 months post-randomization. Biomarkers will be measured in children at 3, 6, 12 and 24 months of age.
Baseline, 3, 6, 9, 12 and 18 months post-randomization, 3, 6, 12 and 24 months of age
Death
Time Frame: Up to Study Exit (up to 60 months of age of child)
Death of all participants will be documented
Up to Study Exit (up to 60 months of age of child)
Change in Dried Blood Spot (DBS) Biomarkers
Time Frame: Baseline, 3, 6, 9, 12 and 18 months post-randomization, 3, 6, 12 and 24 months of age
The main biomarkers to be measured from the dried blood spots is: inflammation markers, endothelial markers of cardiovascular disease, oxidative stress markers, Hb, HbA1C, tumor-associated antigen antibodies, cytochrome P450, p53 tumor-associated antigen (TAA), lipids, metabolomics, MiRNA, heavy metals. DBS biomarkers will be measured in pregnant women at baseline, 24-28 weeks gestation, and 32-36 weeks gestation, and in new mothers when the child is 24-months old. DBS biomarkers will be measured in older adult women at baseline, 3, 6, 9, 12 and 18 months post-randomization. DBS biomarkers will be measured in children at 3, 6, 12 and 24 months of age.
Baseline, 3, 6, 9, 12 and 18 months post-randomization, 3, 6, 12 and 24 months of age
Child Lung Function
Time Frame: 36, 48 and 60 months of age
Lung function measurements will be made using the forced oscillation technique (FOT) with the Tremoflo C-100 device with disposable mouthpieces. FOT is a technique that can identify early changes in the airways. The FOT device measures the relationship between externally applied pressure waves and the resulting air flow to measure respiratory impedance. Values produced at high frequencies correspond to the proximal and large airways, and values produced at low frequencies correspond to distal and small airways. This measurement will be conducted in children in Guatemala.
36, 48 and 60 months of age

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maternal Perceived Stress Scale (PSS)
Time Frame: 3 months to 12 months of age
The 10-item Cohen's Perceived Stress Scale (PPS) assesses the way an individual appraises their life events as stressful (e.g., "In the last month, how often have you felt difficulties were piling up so high that you could not overcome them?") (Cohen, 1983). Likert-level responses ranged from 0 (never) to 4 (very often), meaning a high PPS score would result in a high level of perceived stress. A Spanish language PPS created and tested and found to be valid and reliable (Vallijo et al., 2018).
3 months to 12 months of age
Maternal death
Time Frame: Pregnancy through 42 days post-partum
Death of a woman while pregnant or within 42 days of termination of pregnancy irrespective of the duration and site of the pregnancy.
Pregnancy through 42 days post-partum
Spontaneous abortion
Time Frame: Baseline through 20 weeks gestation
Fetal death before 19 weeks 6 days.
Baseline through 20 weeks gestation
Early preterm birth
Time Frame: Birth
Births at less than 34 weeks completed gestation, among all live births.
Birth
Preterm delivery
Time Frame: Birth
Including preterm birth and stillbirth
Birth
Stillbirth
Time Frame: Up to birth
Any fetal deaths occurring at or after 20 weeks' gestation OR indicated on Serious Adverse Event form OR on Pregnant Woman Medical History form OR on verbal autopsy form.
Up to birth
Neonatal death
Time Frame: Birth through 28 days
Death between birth and 28 days.
Birth through 28 days
Change in fine particulate matter (PM2.5) exposure
Time Frame: Baseline, 3, 5, 9, 12 and 18 months post-randomization, 24, 36, 48, 60 months of age
Personal monitoring equipment will be used to assess exposure to fine particulate matter (PM2.5) over a 24-hour period in intervention and control participants (pregnant women, older adult women, and children). Exposure for pregnant women will be measured at baseline, 24-28 weeks gestation, 32-36 weeks gestation, and 24 months after delivery. Exposure in the child will be measured at 3, 6, 12, 24, 36, 48 and 60 months of age. Exposure in the older adult women will be measured at baseline, 3, 6, 12 and 18 months post-randomization, and at 24 months after delivery. Additionally, PM2.5 in the home will be measured 6 months, 12 months and 24 months after delivery of the child.
Baseline, 3, 5, 9, 12 and 18 months post-randomization, 24, 36, 48, 60 months of age
Change in Carbon monoxide (CO) exposure
Time Frame: Baseline, 3, 5, 9, 12 and 18 months post-randomization, 24, 36, 48, 60 months of age
Personal monitoring equipment will be used to assess exposure to carbon monoxide (CO) over a 24-hour period in intervention and control participants (pregnant women, older adult women, and children). Exposure for pregnant women will be measured at baseline, 24-28 weeks gestation, 32-36 weeks gestation, and 24 months after delivery. Children will be measured up to 12 months after delivery, and at 24, 36, 48 and 60 months of age. Older adult women will be measured up to 12 months after delivery, and at 24 months after delivery. Additionally, CO in the home will be measured 6 months, 12 months and 24 months after delivery of the child.
Baseline, 3, 5, 9, 12 and 18 months post-randomization, 24, 36, 48, 60 months of age
Change in Black carbon (BC) exposure
Time Frame: Baseline, 3, 5, 9, 12 and 18 months post-randomization, 24, 36, 48, 60 months of age
Personal monitoring equipment will be used to assess exposure to black carbon (BC) over a 24-hour period in intervention and control participants (pregnant women, older adult women, and children). Exposure for pregnant women will be measured at baseline, 24-28 weeks gestation, 32-36 weeks gestation, and 24 months after delivery. Children will be measured up to 12 months after delivery, and at 24, 36, 48 and 60 months of age. Older adult women will be measured up to 12 months after delivery, and at 24 months after delivery. Additionally, BC in the home will be measured 6 months, 12 months and 24 months after delivery of the child.
Baseline, 3, 5, 9, 12 and 18 months post-randomization, 24, 36, 48, 60 months of age
Change in Child Blood Pressure
Time Frame: 48 and 60 months of age
Blood pressure will be assessed in the children using automatic sphygmomanometers (OMRON HEM-907XL; Osaka, Japan). The study team will use the procedures adapted from previously validated methods and cardiovascular outcome studies, following recommendations for the American Heart Association and the European Society of Hypertension.
48 and 60 months of age
Change in Messenger Ribonucleic Acid (mRNA) Expression and microRNA in Older Adult Women
Time Frame: Baseline, 18 months post-randomization
Two buccal cell scrapes will be collected by gently scraping the buccal mucosa on both sides of the mouth with a small plastic collection spoon. Nasal turbinate brush samples can be collected using a soft cytobrush on each turbinate. Collection is gentle and causes no discomfort to study participants. Both samples will be processed in the laboratory according to procedures detailed in the protocol. This will occur in the older adult women in an NCI substudy.
Baseline, 18 months post-randomization
Change in Microbiome Operational Taxonomic Units (OTUs) in Older Adult Women
Time Frame: Baseline, 18 months post-randomization
For the oral rinse, participants will vigorously rinse their mouth and the rinsates are collected in a centrifuge tube. The tube is centrifuged and the pellet and supernatant are removed to separate cryovials, labeled and frozen. This will occur in the older adult women in an NCI substudy.
Baseline, 18 months post-randomization
Change in Epigenetics (DNA methylation) in Older Adult Women
Time Frame: Baseline, 18 months post-randomization
Two buccal cell scrapes will be collected by gently scraping the buccal mucosa on both sides of the mouth with a small plastic collection spoon. A 5-mL venous blood sample will be collected in an ethylenediaminetetraacetic acid (EDTA) vacutainer tube by standard clinical venipuncture of a cubital vein. Both samples will be transported and processed in the laboratory according to procedures detailed in the protocol. This will occur in the older adult women in an NCI substudy.
Baseline, 18 months post-randomization
Change in Metabolomics and MicroRNA in Older Adult Women
Time Frame: Baseline, 18 months post-randomization
A 5-mL venous blood sample will be collected in an EDTA vacutainer tube by standard clinical venipuncture of a cubital vein. The sample will be transported and processed in the laboratory according to procedures detailed in the protocol. This will occur in the older adult women in an NCI substudy.
Baseline, 18 months post-randomization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2017

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

June 30, 2026

Study Registration Dates

First Submitted

October 17, 2016

First Submitted That Met QC Criteria

October 24, 2016

First Posted (Estimated)

October 26, 2016

Study Record Updates

Last Update Posted (Actual)

March 26, 2024

Last Update Submitted That Met QC Criteria

March 22, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB00089799
  • 1UM1HL134590-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infant, Low Birth Weight

Clinical Trials on Liquefied petroleum gas (LPG) cookstove

3
Subscribe